ADMA Biologics acquisition history

ADMA acquired the Therapy Business Unit of Biotest Pharmaceuticals Corporation (BPC), a subsidiary of Germany's Biotest AG, turning ADMA into a vertically integrated commercial plasma-products company. The acquired assets included a plasma fractionation and purification plant of FDA-licensed biologics, testing laboratories, warehouses and a commercial-scale monoclonal-antibody facility across two buildings totaling roughly 126,000 square feet on about 15 acres in Boca Raton, Florida; two FDA-licensed products, Nabi-HB (Hepatitis B Immune Globulin) and BIVIGAM (Immune Globulin Intravenous); and a third-party contract-manufacturing and services agreement for a licensed hyperimmune globulin. The Boca Raton plant was already the site where ADMA's own lead candidate, RI-002 (later marketed as ASCENIV), was manufactured. As part of the purchase price, ADMA later transferred two of its Georgia source-plasma collection centers back to BPC, which closed on January 1, 2019.

Upon the completion of this transaction, ADMA believes it will be uniquely positioned to offer a fully vertically integrated plasma products and immune globulin platform in the U.S. This transaction will allow ADMA to work directly with the FDA in efforts to obtain U.S. regulatory approval for RI-002 and remediate the outstanding Warning Letter at the manufacturing facility.Adam Grossman — President and Chief Executive Officer, ADMA Biologics

We believe that ADMA's management team and Board are equipped with the operational expertise required to effectively leverage the acquired manufacturing facilities, and ultimately achieve FDA licensure of RI-002. We are confident that ADMA is ideally suited to maximize the commercial potential of the acquired assets.Dr. Bernhard Ehmer — Chief Executive Officer and Chairman of the Board of Management, Biotest AG